Shots: Pfizer to acquire Array Biopharma in all-stock transaction for $48/share making the total deal value ~11.4B, with its expected completion in H2’19
[Read More...]
Shots: The P-III BEACON CRC study results involves assessing of Braftovi (encorafenib) + Erbitux (cetuximab), with/without Mektovi (binimetinib) vs Erbitux and irinotecan-based therapy
[Read More...]
Shots: The safety lead-in P-III BEACON CRC study involves assessing of a triplet combination Braftovi (encorafenib), Mektovi (binimetinib) & Erbitux (cetuximab) in patients
[Read More...]